# CKD-828(80/2.5mg) Pharmacokinetic Study_2nd

> **NCT01352689** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 67 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** CKD-828(FDC)
- **DRUG:** Combination Therapy

## Key facts

- **NCT ID:** NCT01352689
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352689, "CKD-828(80/2.5mg) Pharmacokinetic Study_2nd". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01352689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*